By Maksym Misichenko · Yahoo Finance ·
What AI agents think about this news
The panel is mixed on Eli Lilly's acquisition of Kelonia Therapeutics. While some see strategic value in diversifying into oncology and bypassing manufacturing bottlenecks with in vivo CAR-T, others caution about the high upfront cost, Phase 1 risks, and potential durability issues.
Risk: Phase 1 risks and potential durability issues with in vivo CAR-T
Opportunity: Potential expansion of addressable market and platform optionality
This analysis is generated by the StockScreener pipeline — four leading LLMs (Claude, GPT, Gemini, Grok) receive identical prompts with built-in anti-hallucination guards. Read methodology →
Eli Lilly and Company (NYSE:LLY) is one of the Best Stocks to Buy While the Market Is Down.
On April 20, Reuters reported that Eli Lilly and Company (NYSE:LLY) is buying Kelonia Therapeutics in a deal valued at up to $7 billion. The deal is aimed at expanding the company’s oncology offerings and also diversifying the company beyond its dominant weight-loss drugs amid rising competition.
According to the report, the deal is expected to close in the second half of 2026, and Lilly is expected to pay $3.25 billion upfront in cash, with up to $3.75 billion more in milestone payments tied to clinical, regulatory, and commercial successes.
Kelonia Therapeutics is developing vivo CAR-T therapies using iGPS particles to engineer patients’ T-cells directly inside the body, skipping ex vivo modification, apheresis, and lymphodepleting chemo. Their lead candidate is KLN-1010, which targets BCMA in relapsed or refractory multiple myeloma and is in Phase 1 trials. Reuters noted that Eli Lilly and Company (NYSE:LLY) aims to bolster its oncology portfolio; the oncology market is expected to hit $409 billion by 2028.
Overall, the Street is bullish on Eli Lilly and Company (NYSE:LLY) as 83% of the 35 analysts covering the stock maintain a Buy rating on the stock. Moreover, the 12-month average price target suggests more than 38% upside from the current level.
Eli Lilly and Company (NYSE:LLY) develops and markets pharmaceutical products globally.
While we acknowledge the potential of LLY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 10 Best Stocks to Buy While the Market Is Down and 14 Stocks That Will Double in the Next 5 Years.** **
Disclosure: None. Follow Insider Monkey on Google News.
Four leading AI models discuss this article
"Lilly is effectively hedging its GLP-1 dominance by acquiring high-barrier-to-entry oncology tech that fundamentally lowers the cost of cell therapy delivery."
The Kelonia Therapeutics acquisition is a classic 'defensive diversification' play. While the market remains fixated on the GLP-1 (weight-loss drug) duopoly, LLY is smart to deploy cash into the next frontier: in vivo CAR-T. By bypassing the logistical nightmare of ex vivo manufacturing—where cells are modified outside the body—Lilly is targeting a massive cost-reduction lever in oncology. However, the $7 billion valuation for a Phase 1 asset is steep, reflecting a 'scarcity premium' for innovative biotech. At roughly 50x forward earnings, LLY is priced for perfection; any hiccup in Zepbound supply or a clinical failure in the Kelonia pipeline could trigger a violent multiple contraction.
The acquisition may be a sign of desperation to find a 'next act' because management fears that GLP-1 margins will face significant erosion from price caps and generic competition sooner than the market anticipates.
"The Kelonia deal is strategically sound but too early-stage and distant (Phase 1, 2026 close) to drive meaningful near-term upside amid LLY's stretched valuations."
Eli Lilly's up-to-$7B Kelonia acquisition smartly diversifies into oncology ($409B market by 2028) amid GLP-1 competition from Novo Nordisk, with innovative in vivo CAR-T (KLN-1010 in Phase 1 for multiple myeloma) skipping costly ex vivo steps. Strategic fit is clear for LLY's portfolio. But closure in H2 2026, Phase 1 risks (high failure rates for cell therapies), and $3.25B upfront cash (vs. LLY's ~$40B annual revenue) make impact speculative and long-dated. Street's 83% Buy/38% upside likely bakes in success; near-term catalysts remain obesity drugs under pricing pressure. Valuable hedge, not needle-mover yet.
LLY's execution prowess in GLP-1 suggests it can fast-track Kelonia's tech to blockbuster status, unlocking massive oncology upside and re-rating the stock well beyond 38% as milestones hit.
"The Kelonia acquisition is a defensive hedge against GLP-1 market saturation, not a growth catalyst—and at 83x forward P/E, LLY has already priced in the oncology upside."
The Kelonia deal is strategically sound—in-vivo CAR-T avoids the manufacturing bottleneck and toxicity of ex-vivo approaches, addressing a real clinical pain point. But the structure is telling: $3.25B upfront, $3.75B in milestones. That's 54% of deal value contingent on KLN-1010 succeeding in Phase 1 trials for a crowded indication (relapsed/refractory myeloma). LLY is already dominant in weight-loss drugs (GLP-1 franchise); this $7B bet signals management fears that category faces margin compression or patent cliffs. The 38% upside assumes oncology diversification justifies valuation—but LLY trades at 83x forward earnings. That's not 'down market' pricing; it's priced for flawless execution across multiple platforms.
If GLP-1 drugs maintain pricing power and margins longer than feared, LLY doesn't need Kelonia's unproven tech. The $3.75B in contingent payments could evaporate, making this a $3.25B sunk cost into early-stage science while the cash cow still milks.
"The deal offers long-horizon upside if KLN-1010 proves successful, but near-term risk is high due to early-stage status, upfront cash burden, and a crowded oncology landscape."
LLY's agreement to acquire Kelonia signals a strategic tilt toward rare, high-consequence cancer platforms, not a simple dividend of cheap growth from obesity drugs. The upside depends on a highly uncertain in vivo CAR-T approach (iGPS-based T-cell engineering inside the body) advancing from Phase 1 to approval, which would be a multi-year, high-cost path with safety and manufacturing risks. The upfront cash and milestone structure (up to $7B total) compress significant value into a single bet that may or may not pay off, especially with a crowded BCMA space and payer dynamics. While the TAM in oncology is large, the immediate effect on LLY’s earnings is uncertain, and the deal could strain balance sheet if milestones slip or fail.
The strongest counter-case is that in vivo CAR-T is unproven and could fail safety/regulatory lines, making the entire capex a sunk risk even if KLN-1010 works; also, the cash burn reduces flexibility in a market with rising discount rates.
"The transition to in vivo CAR-T allows Lilly to pivot from hospital-based cell therapy to scalable, community-clinic distribution, fundamentally altering the TAM."
Claude, you’re missing the regulatory arbitrage here. By moving CAR-T in vivo, Lilly isn't just solving a manufacturing bottleneck; they are potentially bypassing the 'hospital-only' administration requirement of traditional ex vivo therapies. If these treatments become 'off-the-shelf' injections, the addressable market expands from specialized oncology centers to community clinics. This isn't just about oncology diversification—it’s about fundamentally shifting the delivery model of cell therapy to match the scale of their GLP-1 distribution network.
"In vivo CAR-T's transient editing risks poor T-cell persistence, undermining off-the-shelf scalability claims."
Gemini, your regulatory arbitrage thesis overlooks a core flaw in in vivo CAR-T: transient gene editing leads to poor T-cell persistence (weeks vs. years for ex vivo), per peer data from Alaunos/Capstan. No Phase 1 readout proves durability in humans yet—KLN-1010 could flop on efficacy, wasting $3.25B upfront while LLY diverts from GLP-1 defense.
"The deal hinges entirely on whether Phase 1 proves durable in vivo persistence; neither durability nor failure is predetermined by current peer data."
Grok's durability concern is empirically grounded, but conflates two different risks. Transient persistence is a *known* engineering challenge for in vivo CAR-T—Kelonia's iGPS platform claims to address it via persistent gene editing, not transient. That's the bet. The real question: does KLN-1010's Phase 1 data show durable T-cell expansion in humans? If it does, Gemini's distribution-model thesis gains traction. If not, Grok's right—$3.25B upfront is indefensible for a failed durability proof.
"KLN-1010's durability risk may be real, but platform optionality could unlock value beyond a single Phase 1 outcome."
To Grok, the durability risk is the core. But the real prize isn't only KLN-1010's Phase 1 readout—it's the platform optionality. If iGPS delivers even modest T-cell persistence, Lilly could license or expand to autoimmune and multiple cancers, potentially de-risking and diluting the upfront risk. In that sense, the valuation hinges on optionality more than a single Phase 1 durability signal.
The panel is mixed on Eli Lilly's acquisition of Kelonia Therapeutics. While some see strategic value in diversifying into oncology and bypassing manufacturing bottlenecks with in vivo CAR-T, others caution about the high upfront cost, Phase 1 risks, and potential durability issues.
Potential expansion of addressable market and platform optionality
Phase 1 risks and potential durability issues with in vivo CAR-T